We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based biotechnology company BioMarin Pharmaceutical has announced the completion of an underwritten public offering of senior subordinated convertible notes to raise $450m.